Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

The SARS-CoV-2 Omicron (B. 1.1529) variant was designated as a variant of concern (VOC)
by the World Health Organization (WHO) on November 26, 2021. Within two months, it had …

The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …

In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐
CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent …

The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …

Dear Editor, The ongoing SARS-CoV-2 pandemic continues to be a significant threat to
global health. First reported in November 2021, the Omicron variant (B. 1.1. 529) is more …

Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to represent a
global health emergency as a highly transmissible, airborne virus. An important coronaviral …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the
Coronavirus family which caused the worldwide pandemic of human respiratory illness …